CompanyDrug

Bristol-Myers Squibb Secures FDA Approval for Iberdomide Combination in Multiple Myeloma – First‑Ever Nod Based on MRD‑Negative Response Data

CompanyDeals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

CompanyDrug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
CompanyDeals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

CompanyDrug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

CompanyDrug

TJ Biopharma and Biogen Win NMPA Approval for Felzartamab (JINGFEI) in Multiple Myeloma – First Commercial Milestone Under Greater China Licensing Deal

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies
CompanyDeals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

CompanyDeals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

CompanyDeals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

CompanyDrug

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

CompanyDrug

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis